Advances in adjuvant therapy: potential for prognostic and predictive biomarkers

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Melanoma is a significant cause of cancer mortality, with rising incidence and earlier diagnosis.
• Interferon-alfa has been an approved adjuvant therapy for high-risk melanoma for decades, improving survival outcomes.
• Despite benefits, Interferon-alfa's widespread use is limited by toxicity and lack of predictive biomarkers.

Purpose of the Study:

• To review the established role of Interferon-alfa in adjuvant melanoma therapy.
• To highlight the limitations of current adjuvant treatments, including toxicity and biomarker scarcity.
• To discuss emerging therapeutic strategies in melanoma treatment.

Main Methods:

• Review of clinical studies and meta-analyses on Interferon-alfa for adjuvant melanoma.
• Analysis of treatment outcomes, including relapse-free and overall survival.
• Examination of toxicity profiles and the need for prognostic/predictive biomarkers.

Main Results:

• Interferon-alfa consistently improves relapse rates and, to a lesser extent, survival in high-risk melanoma.
• Significant side effects are associated with Interferon-alfa therapy.
• Lack of biomarkers hinders personalized risk-benefit assessments for Interferon-alfa.

Conclusions:

• While Interferon-alfa offers survival benefits, its toxicity necessitates exploration of alternative or refined adjuvant strategies.
• Advances in targeted therapies and immunotherapy are transforming metastatic melanoma treatment.
• Future research priorities include identifying predictive biomarkers and developing novel combination regimens for improved melanoma management.